These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
171 related articles for article (PubMed ID: 24326362)
1. Expression of glucagon-like Peptide 1 receptor and its effects on biologic behavior in pancreatic neuroendocrine tumors. Cases AI; Ohtsuka T; Fujino M; Ideno N; Kozono S; Zhao M; Ohuchida K; Aishima S; Nomura M; Oda Y; Mizumoto K; Tanaka M Pancreas; 2014 Jan; 43(1):1-6. PubMed ID: 24326362 [TBL] [Abstract][Full Text] [Related]
2. Different Hormonal Expression Patterns Between Primary Pancreatic Neuroendocrine Tumors and Metastatic Sites. Kimura H; Ohtsuka T; Fujimoto T; Date K; Matsunaga T; Cases AI; Abe A; Mizuuchi Y; Miyasaka Y; Ito T; Oda Y; Nakamura M; Tanaka M Pancreas; 2016 Aug; 45(7):947-52. PubMed ID: 26684862 [TBL] [Abstract][Full Text] [Related]
3. Activation of glucagon-like peptide-1 receptor inhibits growth and promotes apoptosis of human pancreatic cancer cells in a cAMP-dependent manner. Zhao H; Wei R; Wang L; Tian Q; Tao M; Ke J; Liu Y; Hou W; Zhang L; Yang J; Hong T Am J Physiol Endocrinol Metab; 2014 Jun; 306(12):E1431-41. PubMed ID: 24801389 [TBL] [Abstract][Full Text] [Related]
4. Significance of expression of glucagon-like peptide 1 receptor in pancreatic cancer. Cases AI; Ohtsuka T; Kimura H; Zheng B; Shindo K; Oda Y; Mizumoto K; Nakamura M; Tanaka M Oncol Rep; 2015 Oct; 34(4):1717-25. PubMed ID: 26238361 [TBL] [Abstract][Full Text] [Related]
5. Clinicopathologic and prognostic significance of multiple hormone expression in pancreatic neuroendocrine tumors. Kim JY; Kim MS; Kim KS; Song KB; Lee SH; Hwang DW; Kim KP; Kim HJ; Yu E; Kim SC; Jang HJ; Hong SM Am J Surg Pathol; 2015 May; 39(5):592-601. PubMed ID: 25602797 [TBL] [Abstract][Full Text] [Related]
6. Immunohistochemical Glucagon-like Peptide-1 Receptor Expression in Human Insulinomas. Vesterinen T; Peltola E; Leijon H; Hannula P; Huhtala H; Mäkinen MJ; Nieminen L; Pirinen E; Rönty M; Söderström M; Jaatinen P; Arola J Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37894845 [TBL] [Abstract][Full Text] [Related]
7. Loss of DAXX and ATRX are associated with chromosome instability and reduced survival of patients with pancreatic neuroendocrine tumors. Marinoni I; Kurrer AS; Vassella E; Dettmer M; Rudolph T; Banz V; Hunger F; Pasquinelli S; Speel EJ; Perren A Gastroenterology; 2014 Feb; 146(2):453-60.e5. PubMed ID: 24148618 [TBL] [Abstract][Full Text] [Related]
8. Glucagon-like peptide-1 and its receptor agonist exendin-4 modulate cholangiocyte adaptive response to cholestasis. Marzioni M; Alpini G; Saccomanno S; Candelaresi C; Venter J; Rychlicki C; Fava G; Francis H; Trozzi L; Glaser S; Benedetti A Gastroenterology; 2007 Jul; 133(1):244-55. PubMed ID: 17631146 [TBL] [Abstract][Full Text] [Related]
10. Analysis of lymph node metastasis in pancreatic neuroendocrine tumors (PNETs) based on the tumor size and hormonal production. Tsutsumi K; Ohtsuka T; Mori Y; Fujino M; Yasui T; Aishima S; Takahata S; Nakamura M; Ito T; Tanaka M J Gastroenterol; 2012 Jun; 47(6):678-85. PubMed ID: 22350698 [TBL] [Abstract][Full Text] [Related]
11. Glucagon-Like Peptide-1 Receptor Expression in Normal and Neoplastic Human Pancreatic Tissues. Dal Molin M; Kim H; Blackford A; Sharma R; Goggins M Pancreas; 2016 Apr; 45(4):613-9. PubMed ID: 26495786 [TBL] [Abstract][Full Text] [Related]
12. Met proto-oncogene and insulin-like growth factor binding protein 3 overexpression correlates with metastatic ability in well-differentiated pancreatic endocrine neoplasms. Hansel DE; Rahman A; House M; Ashfaq R; Berg K; Yeo CJ; Maitra A Clin Cancer Res; 2004 Sep; 10(18 Pt 1):6152-8. PubMed ID: 15448002 [TBL] [Abstract][Full Text] [Related]
13. The peptide-hormone glucagon-like peptide-1 activates cAMP and inhibits growth of breast cancer cells. Ligumsky H; Wolf I; Israeli S; Haimsohn M; Ferber S; Karasik A; Kaufman B; Rubinek T Breast Cancer Res Treat; 2012 Apr; 132(2):449-61. PubMed ID: 21638053 [TBL] [Abstract][Full Text] [Related]
14. Incidental diagnosis as prognostic factor in different tumor stages of nonfunctioning pancreatic endocrine tumors. Crippa S; Partelli S; Zamboni G; Scarpa A; Tamburrino D; Bassi C; Pederzoli P; Falconi M Surgery; 2014 Jan; 155(1):145-53. PubMed ID: 24646958 [TBL] [Abstract][Full Text] [Related]
15. Population-level analysis of pancreatic neuroendocrine tumors 2 cm or less in size. Kuo EJ; Salem RR Ann Surg Oncol; 2013 Sep; 20(9):2815-21. PubMed ID: 23771245 [TBL] [Abstract][Full Text] [Related]
18. The expression of GLP-1 receptor mRNA and protein allows the effect of GLP-1 on glucose metabolism in the human hypothalamus and brainstem. Alvarez E; Martínez MD; Roncero I; Chowen JA; García-Cuartero B; Gispert JD; Sanz C; Vázquez P; Maldonado A; de Cáceres J; Desco M; Pozo MA; Blázquez E J Neurochem; 2005 Feb; 92(4):798-806. PubMed ID: 15686481 [TBL] [Abstract][Full Text] [Related]
19. Two small molecule agonists of glucagon-like peptide-1 receptor modulate the receptor activation response differently. Cheong YH; Kim MK; Son MH; Kaang BK Biochem Biophys Res Commun; 2012 Jan; 417(1):558-63. PubMed ID: 22177947 [TBL] [Abstract][Full Text] [Related]
20. Application of the pancreatic adenocarcinoma staging system to pancreatic neuroendocrine tumors. Bilimoria KY; Bentrem DJ; Merkow RP; Tomlinson JS; Stewart AK; Ko CY; Talamonti MS J Am Coll Surg; 2007 Oct; 205(4):558-63. PubMed ID: 17903729 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]